- Home
- CYCN vs ADXN Comparison
CYCN vs ADXN Comparison
Compare CYCN & ADXN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CYCN
- ADXN
- Stock Information
- Founded
- CYCN 2018
- ADXN 2002
- Country
- CYCN United States
- ADXN Switzerland
- Employees
- CYCN N/A
- ADXN N/A
- Industry
- CYCN Biotechnology: Pharmaceutical Preparations
- ADXN Biotechnology: Pharmaceutical Preparations
- Sector
- CYCN Health Care
- ADXN Health Care
- Exchange
- CYCN Nasdaq
- ADXN Nasdaq
- Market Cap
- CYCN 8.0M
- ADXN 8.0M
- IPO Year
- CYCN N/A
- ADXN N/A
- Fundamental
- Price
- CYCN $2.36
- ADXN $10.13
- Analyst Decision
- CYCN
- ADXN Strong Buy
- Analyst Count
- CYCN 0
- ADXN 1
- Target Price
- CYCN N/A
- ADXN $30.00
- AVG Volume (30 Days)
- CYCN 24.8K
- ADXN 61.3K
- Earning Date
- CYCN 11-13-2025
- ADXN 09-01-2025
- Dividend Yield
- CYCN N/A
- ADXN N/A
- EPS Growth
- CYCN N/A
- ADXN N/A
- EPS
- CYCN N/A
- ADXN 0.10
- Revenue
- CYCN $2,174,000.00
- ADXN $278,508.00
- Revenue This Year
- CYCN N/A
- ADXN $86.57
- Revenue Next Year
- CYCN N/A
- ADXN N/A
- P/E Ratio
- CYCN N/A
- ADXN $0.84
- Revenue Growth
- CYCN N/A
- ADXN N/A
- 52 Week Low
- CYCN $1.27
- ADXN $6.51
- 52 Week High
- CYCN $9.47
- ADXN $12.05
- Technical
- Relative Strength Index (RSI)
- CYCN 45.98
- ADXN 61.31
- Support Level
- CYCN $2.30
- ADXN $8.88
- Resistance Level
- CYCN $2.59
- ADXN $10.85
- Average True Range (ATR)
- CYCN 0.20
- ADXN 0.52
- MACD
- CYCN 0.01
- ADXN 0.27
- Stochastic Oscillator
- CYCN 38.14
- ADXN 55.75
About CYCN Cyclerion Therapeutics Inc.
Cyclerion Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of soluble guanylate cyclase (sGC) pharmacology to discover, develop, and commercialize breakthrough treatments for serious and orphan diseases. Its focus is on enabling the full therapeutic potential of next-generation sGC stimulators. Its pipeline products include Olinciguat, Praliciguat, and others.
About ADXN Addex Therapeutics Ltd
Addex Therapeutics Ltd is a clinical-stage biopharmaceutical company. The company is focused on the development and commercialization of an emerging class of novel orally available small-molecule drugs known as allosteric modulators. The company's geographical area of operations includes Switzerland and Europe. The Company operates in one segment, which is the discovery, development, and commercialization of small-molecule pharmaceutical products.